ClinicalTrials.Veeva

Menu

Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer (SITRR)

U

University Hospital, Angers

Status

Unknown

Conditions

Non-small Cell Lung Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT02075957
2012-A00827-36

Details and patient eligibility

About

Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC).

Full description

  • A first blood sample will be taken during the week before the operation. A second blood sample will be taken 4 to 8 weeks after the operation. And in case of relapse, a third sample will be taken. These samples are going to be stored in the collection of biological resources of Angers.
  • Concerning the biopsy of the resected NSLCL, it will be sent to the collection of biological resources of Angers for conservation directly next to the surgery.

Enrollment

192 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Major subject
  • Subject who received resection with primary non-small cell lung cancer at the University Hospital of Angers and whose tumor samples will be stored in collection of biological resources of University Hospital of Angers
  • A written inform consent.

Exclusion criteria

  • Under 18 year old;
  • Pregnant or nursing women;
  • Deprived of liberty;
  • Age under curatorship or guardianship;
  • Unable to consent person;
  • About not carrying a non-small cell lung cancer.

Trial contacts and locations

1

Loading...

Central trial contact

José HUREAUX, Doctor; Amandine AULNETTE, CRA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems